Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 98

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 8
Chunk 98
---
shares of Series A Preferred Stock are issued and outstanding.

Following stockholder approval in July 2024, on
July 30, 2024, the Company filed an Amendment to the Certificate of Incorporation with the Secretary of State of Delaware to effect the
1:12 Reverse Stock Split of the issued and outstanding shares of the Company’s common stock, which was effective as of August 12,
2024. As of the effective time of the 1:12 Reverse Stock Split, every twelve (12) issued and outstanding shares of the Company’s
common stock were automatically combined and converted into one (1) issued and outstanding share of the Company’s common stock.

Following stockholder approval in November 2024,
on February 18, 2025, the Company filed an additional Amendment to the Certificate of Incorporation with the Secretary of State of Delaware
to effect the 1:5 Reverse Stock Split of the issued and outstanding shares of the Company’s common stock, which was effective as
of February 24, 2025. As of the effective time of the 1:5 Reverse Stock Split, every five (5) issued and outstanding shares of the Company’s
common stock were automatically combined and converted into one (1) issued and outstanding share of the Company’s common stock.

No fractional shares of common stock were issued
in connection with the Reverse Stock Splits. All fractional shares were rounded up to the nearest whole share with respect to outstanding
shares of common stock. The Reverse Stock Splits did not change the authorized number of shares of common stock or preferred stock, the
par value of the common stock, or the number of issued and outstanding shares of Series A Preferred Stock. All references to numbers of
shares of the Company’s common stock and per share information in these consolidated condensed financial statements have been retroactively
adjusted, as appropriate, to reflect the Reverse Stock Splits, including reclassifying an amount equal to the reduction in par value of
common stock to additional paid-in capital.

15

Common Stock

January 2025 Offering

On January 28, 2025, the Company entered into
a securities purchase agreement with certain institutional investors pursuant to which the Company sold, in a registered direct offering
priced at-the-market under the rules of Nasdaq, an aggregate of 204,312 shares of common stock at a purchase price of $5.105 per share.
The shares were offered pursuant to a “shelf” registration statement on Form S-3 (Registration No.